The promise of structural genomics in the discovery of new antimicrobial agents.
Structural Genomics stands out among the emerging fields of proteomics since it influences the drug discovery process at so many points. Recent developments in protein expression technologies, x-ray crystallography and NMR spectroscopy provide the essential elements for high-throughput structure determination platforms. Bioinformatics methods to interrogate the resulting data will provide comprehensive, genome-wide databases of protein structure. Genomic sequencing and methods for high-throughput expression and protein purification are furthest advanced for microbial genes and so these have been the early targets for structural genomics initiatives. The information will be invaluable in understanding gene function, designing broad-spectrum small molecule inhibitors and in better understanding drug-host interactions.
Buchanan
S G
SG
Director of Bioinformatics, Structural GenomiX, San Diego, CA 92121, USA. sean@stromix.com
Sauder
J M
JM
Harris
T
T
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000737:chemistry / Q000235:genetics; D015195:Drug Design; D016680:Genome, Bacterial; D023281:Genomics; D011487:Protein Conformation; D011550:Pseudomonas aeruginosa / Q000235:genetics
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins